Chemoprevention of breast cancer with fenretinide

Drugs

Volumn 61, Issue 7, 2001, Pages 909-918

  Torrisi, R ^a   Decensi, A ^a   Formelli, F ^b   Camerini, T ^b   De Palo, G ^b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b National Tumour Institute   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FENRETINIDE; RALOXIFENE; RETINOID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN C; TAMOXIFEN;

APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RISK; CARCINOGENESIS; CELL GROWTH; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; GROWTH INHIBITION; HUMAN; PREMENOPAUSE; REVIEW; SECONDARY PREVENTION; SKIN DISEASE;

EID: 0034992191     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161070-00002     Document Type: Review

References (63)

1. Polychemotherapy for early breast cancer: An overview of the randomized trials
2. Tamoxifen for early breast cancer: An overview of the randomized trials
3. The taxanes: An update
4. Efficacy of screening mammography among women aged 40 to 49 years and 50 to 69 years: Comparison of relative and absolute benefit
5. Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study
6. Tamoxifen prevention of breast cancer: An instance of the fingerpost
7. Chemoprevention of cancer with retinoids
8. Cancer chemoprevention: Progress and promise
9. The effect of Raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial
10. Breast cancer prevention trials
11. A decade of molecular biology of retinoic acid receptors
12. Chemoprevention of cancer
13. Aberrant retinoid signaling and breast cancer: The view from outside the nucleus
14. A new class of retinoids with selective inhibtion of AP-1 inhibits proliferation
15. Suppression of retinoic- acid receptor- in premalignant oral lesions and its upregulation by isotretinoin
16. Retinoic acid receptor- expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide
17. Progressive decrease in nuclear retinoic acid receptor messenger RNA level during breast carcinogenesis
18. Loss of retinoic acid receptor beta expression in breast cancer and morphologically normal adjacent tissue but not in the breast tissue distant from the cancer
19. Unique anti-Activator Protein-1 activity of retinoic acid receptor
20. Signal relay by retinoic acid receptor and in the retinoic acid-induced expression of insulin-like growth factor-binding protein-3 in breast cancer cells
21. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids)
22. N-(4-hydroxypheynl) retinamide), a new retinoid for prevention of breast cancer in the rat
23. Clinical development plan: N-(4-hydroxyphenyl)retinamide (4-HPR)
24. N-(4-hydroxyphenyl) retinamide (4-HPR) -mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma
25. 4-Hydroxyphenyl-retinamide is a highly selective activator of retinoid receptors
26. Mediation of N-(4-hydroxyphenyl) retinamide-induced apoptosis in human cancer cells by different mechanisms
27. Retinoids and apoptosis: Implications for cancer chemoprevention and therapy
28. Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells
29. N-(4-hydroxyphenyl) retinamide activation of transforming growth factor- beta and induction of apoptosis in human breast cancer cells
30. Induction of apoptosis by N-(hydroxyphenyl)retinamide and its association with reactive oxygen species, nuclear retinoic acid receptors, and apoptosis-related genes in human prostate carcinoma cells
31. Suppression of cell proliferation and telomerase activity in 4-(hydroxyphenyl) retinamide-treated mammary tumors
32. Inhibition of aberrant proliferation and induction of apoptosis in HER-2/neu oncogene transformed human mammary epithelial cells by N-(4-hydroxyphenyl)retinamide
33. Effect of retinoid analogues on mammary cancer in transgenic mice bearing c-neu transfected breast cancer oncogene
34. Distribution of fenretinide in the mammary gland of breast cancer patients
35. Contralateral breast cancer: Annual incidence and risk parameters
36. Plasma retinol reduction by the synthetic retinoid fenretinide: A one year follow-up study
37. Phase I trial of fenretinide (HPR) in breast cancer patients
38. Tamoxifen and Fenretinide in women with metastatic breast cancer
39. Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer
40. In vitro interaction of fenretinide with plasma retinol-binding protein and its functional consequences
41. Effects of chronic administration of N-(4-hydroxyphenyl)retinamide (4-HPR) in rats on vitamin A metabolism in eye
42. Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid fenretinide in breast cancer patients
43. Five-year administration of fenretinide of fenretinide: Pharmacokinetics and effects on plasma retinol concentrations
44. Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrual
45. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer
46. Can fenretinide protect women against ovarian cancer?
47. Vitamin A analogue for breast cancer prevention: A grade of F or incomplete?
48. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor-I levels in breast cancer patients
49. Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients
50. Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl) retinamide in human breast cancer cell lines
51. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer
52. Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer
53. Safety of the synthetic retinoid fenretinide: Long-term results from a controlled clinical trial for the prevention of contralateral breast cancer
54. Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate endpoint
55. Pilot trial of the safety and tolerability, and retinoid levels of N-(4-hydroxyphenyl)retinamide in combination with tamoxifen in patients at high risk of developing invasive breast cancer
56. Chemoprevention of breast cancer with fenretinide (4-HPR): Study of long-term visual and ophthalmologic tolerability
57. Effect of the synthetic retinoid fenretinide on dark adaptation and the ocular surface
58. Effects of fenretinide (4-HPR) on dark adaptation
59. Chemoprevention of mammary carcinogensis in the rat: Combined use of raloxifene and 9-cis retinoic acid
60. Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats
61. Fenretinide (FEN) versus placebo in postmenopausal breast cancer patients receiving adjuvant tamoxifen (TAM), an Eastern Cooperative Oncology Group Phase III Intergroup Trial (EB193, INT-0151)
62. Validation studies for models projecting the risk of invasive and total breast cancer incidence
63. A randomised trial of fenretinide in HRT users using IGF-I as a surrogate biomarker